Phenylcinnamides as novel antimitotic agents

Journal of Medicinal Chemistry

Volumn 53, Issue 10, 2010, Pages 3964-3972

  Leslie, Benjamin J ^a   Holaday, Clinton R ^a   Nguyen, Tran ^a   Hergenrother, Paul J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN A4; GLYCOPROTEIN P; PACLITAXEL; PHENYLCINNAMIDE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL VIABILITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEUKEMIA CELL LINE; MICROTUBULE; MITOSIS; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; ROOM TEMPERATURE; STRUCTURE ACTIVITY RELATION; UPREGULATION;

ANIMALS; ANTIMITOTIC AGENTS; BLOOD-BRAIN BARRIER; CATTLE; CINNAMATES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HELA CELLS; HUMANS; MICROTUBULES; P-GLYCOPROTEIN; PERMEABILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS; U937 CELLS;

EID: 77952696174     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901805m     Document Type: Article

References (46)

1. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 1-17
2. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265
3. Jordan, M. A.; Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy Curr. Opin. Cell Biol. 1998, 10, 123-130
4. Giannakakou, P.; Sackett, D.; Fojo, T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents J. Natl. Cancer Inst. 2000, 92, 182-183
5. Mooberry, S. L.; Weiderhold, K. N.; Dakshanamurthy, S.; Hamel, E.; Banner, E. J.; Kharlamova, A.; Hempel, J.; Gupton, J. T.; Brown, M. L. Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole Mol. Pharmacol. 2007, 72, 132-140
6. Deeken, J. F.; Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin. Cancer Res. 2007, 13, 1663-1674
7. Dumontet, C.; Duran, G. E.; Steger, K. A.; Beketic-Oreskovic, L.; Sikic, B. I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol) Cancer Res. 1996, 56, 1091-1097
8. Matesanz, R.; Barasoain, I.; Yang, C. G.; Wang, L.; Li, X.; de Ines, C.; Coderch, C.; Gago, F.; Barbero, J. J.; Andreu, J. M.; Fang, W. S.; Diaz, J. F. Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel Chem. Biol. 2008, 15, 573-585
9. Miller, D. S.; Bauer, B.; Hartz, A. M. S. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy Pharmacol. Rev. 2008, 60, 196-209
10. Pellegrini, F.; Budman, D. R. Review: tubulin function, action of antitubulin drugs, and new drug development Cancer Invest. 2005, 23, 264-273
11. Rice, A.; Liu, Y.; Michaelis, M. L.; Himes, R. H.; Georg, G. I.; Audus, K. L. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ J. Med. Chem. 2005, 48, 832-838
12. Tong, Y.-G.; Zhang, X.-W.; Geng, M.-Y.; Yue, J.-M.; Xin, X.-L.; Tian, F.; Shen, X.; Tong, L.-J.; Li, M.-H.; Zhang, C.; Li, W.-H.; Lin, L.-P.; Ding, J. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin Mol. Pharmacol. 2006, 69, 1226-1233
13. Mulligan, J. M.; Greene, L. M.; Cloonan, S.; Mc Gee, M. M.; Onnis, V.; Campiani, G.; Fattorusso, C.; Lawler, M.; Williams, D. C.; Zisterer, D. M. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines Mol. Pharmacol. 2006, 70, 60-70
14. Beyer, C. F.; Zhang, N.; Hernandez, R.; Vitale, D.; Lucas, J.; Nguyen, T.; Discafani, C.; Ayral-Kaloustian, S.; Gibbons, J. J. TTI-237, a novel microtubule-active compound with in vivo antitumor activity Cancer Res. 2008, 68, 2292-2300
15. Liberatore, A.-M.; Coulomb, H.; Pons, D.; Dutruel, O.; Kasprzyk, P. G.; Carlson, M.; Nelson, A. S.; Newman, S. P.; Stengel, C.; Auvray, P.; Hesry, V.; Foll, B.; Narboux, N.; Morlais, D.; Le Moing, M.; Bernetiere, S.; Dellile, R.; Camara, J.; Ferrandis, E.; Bigg, D. C.; Prevost, G. P. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents Mol. Cancer Ther. 2008, 7, 2426-2434
16. Morris, P. G.; Fornier, M. N. Microtubule active agents: beyond the taxane frontier Clin. Cancer Res. 2008, 14, 7167-7172
17. Dothager, R. S.; Putt, K. S.; Allen, B. J.; Leslie, B. J.; Nesterenko, V.; Hergenrother, P. J. Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest J. Am. Chem. Soc. 2005, 127, 8686-8696
18. Goto, H.; Tomono, Y.; Ajiro, K.; Kosako, H.; Fujita, M.; Sakurai, M.; Okawa, K.; Iwamatsu, A.; Okigaki, T.; Takahashi, T.; Inagaki, M. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation J. Biol. Chem. 1999, 274, 25543-25549
19. Bradbury, E. M. Reversible histone modification and the chromosome cell cycle BioEssays 1992, 14, 9-16
20. Teicher, B. A. Newer cytotoxic agents: attacking cancer broadly Clin. Cancer Res. 2008, 14, 1610-1617
21. Schwartz, G. K.; Shah, M. A. Targeting the cell cycle: a new approach to cancer therapy J. Clin. Oncol. 2005, 23, 9408-9421
22. Perez de Castro, I.; de Carcer, G.; Malumbres, M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy Carcinogenesis 2007, 28, 899-912
23. Tao, W. The mitotic checkpoint in cancer therapy Cell Cycle 2005, 4, 1495-1499
24. Robinson, J.; Engelborghs, Y. Tubulin polymerization in dimethyl sulfoxide J. Biol. Chem. 1982, 257, 5367-5371
25. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening Nat. Protoc. 2006, 1, 1112-1116
26. Ishiguro, K.; Ando, T.; Watanabe, O.; Goto, H. Specific reaction of [alpha],[beta]-unsaturated carbonyl compounds such as 6-shogaol with sulfhydryl groups in tubulin leading to microtubule damage FEBS Lett. 2008, 582, 3531-3536
27. Watanabe, H.; Watanabe, H.; Usui, T.; Kondoh, M.; Osada, H.; Kitahara, T. Synthesis of pironetin and related analogs: studies on structure-activity relationships as tubulin assembly inhibitors J. Antibiot. 2000, 53, 540-545
28. Clark, D. E.; Doherty, A. M.; Bock, M. G.; Desai, M. C.; Overington, J.; Plattner, J. J.; Stamford, A.; Wustrow, D.; Young, H. Computational Prediction of Blood-Brain Barrier Permeation. In Annual Reports in Medicinal Chemistry; Academic Press: New York, 2005; Vol. 40, pp 403 - 415.
29. Norinder, U.; Haeberlein, M. Computational approaches to the prediction of the blood-brain distribution Adv. Drug Delivery Rev. 2002, 54, 291-313
30. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport Properties J. Med. Chem. 2000, 43, 3714-3717
31. Cruciani, G.; Pastor, M.; Guba, W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds Eur. J. Pharm. Sci. 2000, 11, S29-S39
32. Kang, S.-H.; Cho, H. T.; Devi, S.; Zhang, Z.; Escuin, D.; Liang, Z.; Mao, H.; Brat, D. J.; Olson, J. J.; Simons, J. W.; LaVallee, T. M.; Giannakakou, P.; Van Meir, E. G.; Shim, H. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model Cancer Res. 2006, 66, 11991-11997
33. Chamaon, K.; Stojek, J.; Kanakis, D.; Braeuninger, S.; Kirches, E.; Krause, G.; Mawrin, C.; Dietzmann, K. Micromolar concentrations of 2-methoxyestradiol kill glioma cells by an apoptotic mechanism, without destroying their microtubule cytoskeleton J. Neuro-Oncol. 2005, 72, 11-16
34. Zou, H.; Zhao, S.; Zhang, J.; Lv, G.; Zhang, X.; Yu, H.; Wang, H.; Wang, L. Enhanced radiation-induced cytotoxic effect by 2-ME in glioma cells is mediated by induction of cell cycle arrest and DNA damage via activation of ATM pathways Brain Res. 2007, 1185, 231-238
35. Lis, A.; Ciesielski, M. J.; Barone, T. A.; Scott, B. E.; Fenstermaker, R. A.; Plunkett, R. J. 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro Cancer Lett. 2004, 213, 57-65
36. Kumar, A. P.; Garcia, G. E.; Orsborn, J.; Levin, V. A.; Slaga, T. J. 2-Methoxyestradiol interferes with NF{kappa}B transcriptional activity in primitive neuroectodermal brain tumors: implications for management Carcinogenesis 2003, 24, 209-216
37. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation Curr. Opin. Oncol. 2000, 12, 450-458
38. Gupte, A.; Mumper, R. J. Copper chelation by d -penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells Free Radical Biol. Med. 2007, 43, 1271-1278
39. Huang, Y.; Ibrado, A. M.; Reed, J. C.; Bullock, G.; Ray, S.; Tang, C.; Bhalla, K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells Leukemia 1997, 11, 253-257
40. Jordan, M. A.; Kamath, K. How do microtubule-targeted drugs work? An overview Curr. Cancer Drug Targets 2007, 7, 730-742
41. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-Glycoprotein: from genomics to mechanism Oncogene 2003, 22, 7468-7485
42. Alvarez, M.; Paull, K.; Monks, A.; Hose, C.; Lee, J. S.; Weinstein, J.; Grever, M.; Bates, S.; Fojo, T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J. Clin. Invest. 1995, 95, 2205-2214
43. Mitchison, T. J. Mitchison Lab Protocols. http://mitchison.med.harvard. edu/protocols.html.
44. Jackman, J.; OConnor, P. M. Methods for synchronizing cells at specific stages of the cell cycle Curr. Protoc. Cell Biol. 2003, 11-14 (Unit 8.3)
45. Lobert, S.; Correia, J. J. Methods for Studying Vinca Alkaloid Interactions with Tubulin. In Microtubule Protocols; Springer: Secaucus, NJ, 2007; pp 261 - 280.
46. National Center for Biotechnology Information. http://pubchem.ncbi.nlm. nih.gov/.